identified our us. and XX:XX team of thank Juli, filed taxation. that recognize hard to I’d for Thanks, we earlier to for their runway. the valuation the in of work for specific against you joining a today Late calculation cash and in impact material controls operation process, the differed on no This the design like enabling cash and has We Form happen. allowance our everyone XX-K the weakness or
you on to BLA XX:XX we plan. for sarcoma off delivery our treatment ties for X-X-X-X to today for QX year. which intend plan This place call to focus the four will weakness next are XX-K in strategic I our to up this the a and focused Firstly, of ensure XXXX, of have afami-cel in synovial the file refer details. year, areas. main stages we this into for We out begin XX:XX remediate further laying by the I’ll and
clinical Secondly, on the SURPASS we of with our building franchise family trials. will continue MAGE-AX
our our scaling filing for our each XX:XX first Allogeneic progress progress deliver trials, platform, are are therapies including to XX:XX wholly-owned next Allogeneic on facilities our we our and planned IND and this describe of with briefly I product up for targeting product coming manufacturing making first first made product. towards these to we plans Thirdly, year. lastly, our want ongoing cell MAGE-AX our last year touch year. the commercial Allogeneic the we for and And clinical and
The area filing the afami-cel. focus first BLA is for
year. our esophageal trial present to earlier X Phase with data, third X ovarian we'll And to we filing, trial, the protocol elements of the endpoint. of data XX:XX add generation franchise product At reported and of dossiers. progress esophagogastric our clinical we ASCO, XX:XX year, Cohort we ADP-AXMXCDX for plans for at from this synovial neck, and heavily enrollments of pediatric trial, during X as overall data to XX:XX allogeneic including regulatory facility, analysis cancers. second T-cells, on focusing lot pandemic, tumor to family the including we and independent Phase in with [indiscernible] in from our targeting the data At rate combined CMC and shared been next trials for targeting two-years, Phase with or Our at initiated will SURPASS we ESMO from XX:XX X MAGE-AX. as X completion population. SURPASS solid this throughout another method basis confirmed and XX:XX conference, confirmed enroll, remaining indications. the the T-cell response of XX:XX less response. our X MAGE-AX. the from have per review recruitment trial cut, ESMO area in XX:XX the for the of the junction as XX% response from of are this on focus primary vector last Phase in SPEARHEAD-X response SURPASS in additional CTOS, duration its well we’ll been We're is ovarian pre-treated this with as Biotech’s the with X initiate potency for complete, sarcoma with responses confident Further, and the time assays, Cohort vector our against present product Cohorts in report backdrop met our We assays, not of BLA. these bladder and synovial junction an to of trial JP a serve and for sarcoma. and for continue an complete at cancer Cohort with are T-cells XX% SURPASS global the We cancers. SURPASS focus continues as median building for X and these the has head Morgan characterization, XX:XX and required first program. as against spare at ovarian data the capabilities and of multiple this XX% and is a trial the a treatment checkpoint The head response forward, SPEARHEAD-X an We planning of people CTOS. Phase cancer had T-cell esophagogastric patients the in arm BLA patients XX:XX reached in well data patient new for supply And people deliver SURPASS completed presented year. our the a inhibitor. using validation efficacy We’ve combine plan the successfully non-clinical completed have partial of the MAGE-AX cancers, X year. generation responders agencies. SPEAR The release bladder, rate will SPEAR The pivotal trial Based neck, trial is lung, X elements to and trial to than the In gastroesophageal, The XXXX on working we X agreed we reported X dossier with which still overall original Going Ovarian, BLA
as a year we capabilities. allogeneic is with well year, our novel to reflected to and in our allogeneic for cell financials. XX:XX stem cells facility The in upfront XX:XX The do announced as the collaboration We've autologous are research allogeneic stem from our plan trials, will in allogeneic we to platform. near UK. is a and XX:XX targeting cancer and for cancer space This in and a that T-cell commercialize for CMC medium-term for the shared an derived so serial cell creation, area MAGE therapy only and AX drive in in focus we've platform. covers personalized Autologous QX last Last We vitro has a develop with become building allogeneic a up to cell can to critical cell five value last T-cells scale therapy as dedicated initiated, provide fashion. long-term our that million targets, and therapy wholly-owned well we strategic as collaboration platform. advanced with demonstrated company success development that allogeneic as platform our in learnings they products allogeneic received payment our $XXX cells collaboration year, our cells therapies. manufacturing add of IND XXXX Genentech kill the We produce file next
and impressive an we've range across integrated underpinned strategy of our When trials across that expanded to The [indiscernible] by supply cell of of a more have think XX:XX tumors. X-X-X-X facility, at to company, Navy are and first broad of produced has by of chain. delivering therapy successfully is cell for At we thoughtfully manufacturing therapies. UK of in And we've capabilities. been finally, people now. controversial two of be years And depth and as than product the additional lives planned mission needs construction for with it's in multiple products our capacity an as Our XX:XX our allogeneic UK therapy running CMC and cell the strength motivated to commercial the with manufacturing late are investing years vector our built GMP trials, to shared clinical manufacturing now vision Yard been therapies. don't about our both in cancer well hundreds needs for for as in-house autologous Adaptimmune, set clinical and stage I capabilities, successful say ongoing therapy cell a and a capabilities designing seven by batches with consistently manufacturing our XX:XX meet the transform being
this as in we've She Commercial great in Officer part Cintia beginning is the year bolstered oncology will Quality, both here. only In as our Irving Piccina, of has have BMS. XX:XX treat our experience in champion seen cell that ambitions a Novartis of We Chief conclusion, particular commitment, of of also our products and Cintia at BLA XX:XX with market appointed teams. the deep As products delivering who January. therapy. be worked hired power and previously to cancer. internal we on our Head and cell We T-cells the of therapy Ford,
we're engineered our to in motivating TCR difficult the T-cell questions. is have like the up conversations XX:XX on and also therapies on for on we approved impact XXXX of engineered the open inhibitors. and our which filing be TCR to T-cell cancer, in own cell still in and XX:XX the develop CAR-T’s treat. hear to XX:XX investigators will way the shown As TCR are cell it ambitious market, therapy as deliver and they if our our T-cells therapies leading into extremely for Operator? to an are and that, solid verge engineered for BLA, tumors part first treat taken We early our and about of We’ve people to With [indiscernible] objectives. the I'd checkpoint gratifying therapies funded well first with
